Azienda Socio Sanitaria Territoriale Di Cremona

At Azienda Socio Sanitaria Territoriale Di Cremona, the strongest research focus is neoplasms, with trials spanning breast cancer, lung cancer, prostate cancer, renal cell carcinoma, urothelial cancer, gastric cancer, and pancreatic cancer. These studies are designed to test new treatment approaches, compare them with current standards, and improve outcomes in both advanced and early-stage disease.

• New targeted and immunotherapy combinations for advanced non-small cell lung cancer and small-cell lung cancer
• Therapy optimization in breast cancer, including hormone receptor-positive, HER2-negative, HER2-positive, and triple-negative disease
• Studies in prostate cancer and metastatic castration-resistant prostate cancer aimed at improving disease control
• Comparisons of treatment strategies in renal cell carcinoma, urothelial carcinoma, and gastroesophageal cancers

This oncology program reflects a broad effort to advance precision medicine, strengthen treatment effectiveness, and expand options for patients with difficult-to-treat cancers.

The site also conducts research in hemic and lymphatic diseases, including acute leukemia, myelodysplastic syndromes, and treatment-related blood complications. These trials are focused on improving survival, reducing transfusion needs, and supporting better tolerance of cancer therapy.

• Studies in acute lymphoblastic leukemia and acute myeloid leukemia evaluating more effective treatment strategies
• Research in myelodysplastic syndromes aimed at reducing anemia and transfusion dependence
• Trials addressing chemotherapy-induced thrombocytopenia to help patients stay on schedule with cancer treatment
• Work on improving measurable disease response and deeper remission in blood cancers

These studies support a practical goal: making hematologic cancer care more effective while limiting treatment-related complications.

Research in digestive system diseases is centered on colorectal cancer, gastric cancer, gastroesophageal junction cancer, and pancreatic cancer. The trials are designed to improve treatment response, refine postoperative care, and evaluate whether newer drug combinations can extend survival.

• Post-surgery studies in colon cancer using circulating tumor DNA to guide treatment decisions
• Trials in gastric and gastroesophageal cancer testing targeted and immune-based approaches
• Research in pancreatic adenocarcinoma focused on first-line and maintenance treatment strategies
• Studies in colorectal cancer evaluating ways to improve disease-free survival and detect residual disease

This is an active area of translational research at the Cremona hospital site, with a strong emphasis on biomarker-driven treatment and better long-term control of gastrointestinal malignancies.

The portfolio includes multiple trials in respiratory tract diseases, especially non-small cell lung cancer, metastatic lung cancer, and resectable lung cancer. These studies are exploring new combinations of targeted therapy, immunotherapy, and chemotherapy to improve response and survival.

• Studies in advanced and metastatic NSCLC comparing newer treatment combinations with standard care
• Trials in resectable NSCLC assessing approaches to improve surgical outcomes and tumor response
• Research in small-cell lung cancer focused on survival benefit with novel systemic therapy
• Biomarker-informed studies aimed at matching treatment to tumor characteristics

The overall goal is to improve outcomes in lung cancer through more personalized and effective treatment strategies.

A major theme at Azienda Socio Sanitaria Territoriale Di Cremona is genitourinary oncology, with research in prostate cancer, renal cell carcinoma, and urothelial cancer. These trials aim to improve disease control, delay progression, and support better treatment choices for both advanced and earlier-stage disease.

• Studies in metastatic prostate cancer examining hormone-based and targeted treatment combinations
• Trials in renal cell carcinoma evaluating immunotherapy-based and sequence-based treatment strategies
• Research in urothelial carcinoma testing new antibody-drug and immunotherapy combinations
• Work in non-muscle invasive bladder cancer focused on preventing recurrence and improving event-free survival

This research area reflects a strong commitment to advancing personalized cancer care for patients with urologic malignancies.

The site is also involved in cardiovascular diseases and venous thromboembolism research, including studies in heart failure and pulmonary embolism. These trials are aimed at improving symptom control, preventing recurrence, and reducing serious complications.

• Research in HFpEF and HFmrEF with obesity focused on better heart failure outcomes
• Trials in acute pulmonary embolism evaluating safer and more effective treatment approaches
• Studies on preventing recurrent venous thromboembolism after a first clotting event
• Work that explores treatment balance between effectiveness and bleeding risk

These cardiovascular studies aim to improve everyday clinical care for patients with heart and clotting disorders.

Beyond cancer-focused work, the research portfolio includes bacterial infections such as bacteremia, along with supportive care studies that help patients tolerate treatment better. The purpose is to improve infection management and strengthen supportive treatment during complex illness.

• Studies in bloodstream infections comparing antibiotic strategies for resistant bacteria
• Supportive care research aimed at maintaining treatment continuity in patients receiving chemotherapy
• Clinical work that addresses complications affecting overall cancer care delivery
• Improving outcomes for patients with serious infection while limiting unnecessary treatment burden

This area adds an important infectious disease and supportive medicine dimension to the clinical research program at the Cremona site.

The remaining studies cover selected areas such as nervous system diseases, musculoskeletal diseases, and conditions that are not easily grouped into a single specialty. These include research on pain, rare disease, and broader treatment safety questions.

• Trials in chronic low back pain exploring better symptom relief
• Research in Mucopolysaccharidosis Type II focused on long-term safety and tolerability
• Studies that do not fit a single therapeutic category but still address important clinical needs
• Work supporting better management of persistent symptoms and complex chronic conditions

These projects broaden the research profile of Azienda Socio Sanitaria Territoriale Di Cremona beyond oncology and reflect a wider interest in patient-centered care.